Trastuzumab duocarmazine (SYD985) demonstrated highly in vitro effectiveness in killing cancer cells expressing different levels of HER2, through a bystander killing of HER2-negative cells, and a superiority to T-DM1, with a 10–70-fold increase in potency in BC patient-derived xenografts models [61]. Here, ERBB2 is linked to breast cancer.